TABLE OF CONTENTS
1 INTRODUCTION 57
1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF THE EUROPE DRUG MODELING SOFTWARE MARKET 57
1.4 CURRENCY AND PRICING 59
1.5 LIMITATIONS 59
1.6 MARKETS COVERED 59
2 MARKET SEGMENTATION 62
2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELING 69
2.7 COMPONENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 71
2.10 MARKET APPLICATION COVERAGE GRID 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
3.1 PORTER'S FIVE FORCES MODEL 78
3.2 VALUE CHAIN ANALYSIS 79
3.3 REGULATORY STANDARDS 80
3.4 TECHNOLOGICAL TRENDS 81
3.5 BENEFITS OF DRUG MODELING SOFTWARE 82
4 MARKET OVERVIEW 83
4.1 DRIVERS 85
4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 85
4.1.2 RISING DEMAND FOR NOVEL THERAPIES 87
4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 88
4.2 RESTRAINTS 89
4.2.1 LACK OF QUALITY DATA BASE 89
4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 89
4.3 OPPORTUNITIES 90
4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 90
4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 91
4.4 CHALLENGES 91
4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 91
4.4.2 CHALLENGES WITH MODEL INTERPRETATION 92
5 EUROPE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 93
5.1 OVERVIEW 94
5.1.1 SOFTWARE 97
5.1.1.1 INTEGRATED 98
5.1.1.2 STANDALONE 98
5.1.1.3 LIGAND BASED 98
5.1.1.4 STRUCTURE BASED 98
5.2 SERVICES 98
5.2.1 PROFESSIONAL SERVICES 99
5.2.1.1 CONSULTING AND TRAINING 100
5.2.1.2 INTEGRATION AND IMPLEMENTATION 100
5.2.1.3 SUPPORT AND MAINTENANCE 100
5.2.2 MANAGED SERVICES 100
6 EUROPE DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 101
6.1 OVERVIEW 102
6.2 WINDOWS 105
6.3 LINUX 105
6.4 MAC OS 106
6.5 OTHERS 107
7 EUROPE DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 108
7.1 OVERVIEW 109
7.2 CLOUD BASED 112
7.3 HYBRID-BASED 112
7.4 ON-PREMISES 113
8 EUROPE DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 114
8.1 OVERVIEW 115
8.2 LARGE ENTERPRISE SIZE 118
8.3 SMALL & MEDIUM ENTERPRISE SIZE 118
9 EUROPE DRUG MODELING SOFTWARE MARKET, BY APPLICATION 120
9.1 OVERVIEW 121
9.2 GRAPHICAL MOLECULAR MODELING 124
9.3 GENE SEQUENCE ANALYSIS 124
9.4 PROTEIN MODELING 125
9.5 MODELING CRYSTAL STRUCTURES 126
9.6 CHEMINFORMATICS 127
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 128
9.8 GAS & SOLUTION PHASE REACTION 128
9.9 MEDICAL IMAGING 129
9.10 OTHERS 130
10 EUROPE DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 131
10.1 OVERVIEW 132
10.2 SUBSCRIPTION BASED 135
10.2.1 ANNUALLY SUBSCRIPTION 136
10.2.2 MONTHLY SUBSCRIPTION 136
10.3 ONE-TIME LICENSE 136
10.3.1 GROUP LICENSE 137
10.3.2 DESKTOP LICENSE 137
10.3.3 OTHERS 137
11 EUROPE DRUG MODELING SOFTWARE MARKET, BY END USER 138
11.1 OVERVIEW 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 142
11.2.1 LARGE ENTERPRISE SIZE 143
11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 143
11.3 CONTRACT RESEARCH ORGANIZATIONS 143
11.3.1 LARGE ENTERPRISE SIZE 144
11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 144
11.4 RESEARCH INSTITUTES 144
11.4.1 LARGE ENTERPRISE SIZE 145
11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 145
11.5 REGULATORY AUTHORITIES 145
11.5.1 LARGE ENTERPRISE SIZE 146
11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.6 OTHERS 147
11.6.1 LARGE ENTERPRISE SIZE 148
11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 148
12 EUROPE DRUG MODELING SOFTWARE MARKET, BY REGION 149
12.1 EUROPE 150
12.1.1 GERMANY 161
12.1.2 FRANCE 166
12.1.3 U.K. 171
12.1.4 ITALY 176
12.1.5 RUSSIA 181
12.1.6 SPAIN 186
12.1.7 TURKEY 191
12.1.8 NETHERLANDS 196
12.1.9 SWITZERLAND 201
12.1.10 BELGIUM 206
12.1.11 POLAND 211
12.1.12 SWEDEN 216
12.1.13 DENMARK 221
12.1.14 FINLAND 226
12.1.15 NORWAY 231
12.1.16 REST OF EUROPE 236
13 EUROPE DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 237
13.1 COMPANY SHARE ANALYSIS: EUROPE 237
14 SWOT ANALYSIS 238
15 EUROPE DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 239
15.1 DASSAULT SYSTEMES 239
15.1.1 COMPANY SNAPSHOT 239
15.1.2 REVENUE ANALYSIS 239
15.1.3 COMPANY SHARE ANALYSIS 240
15.1.4 PRODUCT PORTFOLIO 240
15.1.5 RECENT DEVELOPMENT 240
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 241
15.2.1 COMPANY SNAPSHOT 241
15.2.2 REVENUE ANALYSIS 241
15.2.3 COMPANY SHARE ANALYSIS 242
15.2.4 PRODUCT PORTFOLIO 242
15.2.5 RECENT DEVELOPMENTS 242
15.3 CERTARA, USA. 243
15.3.1 COMPANY SNAPSHOT 243
15.3.2 REVENUE ANALYSIS 243
15.3.3 COMPANY SHARE ANALYSIS 244
15.3.4 PRODUCT PORTFOLIO 244
15.3.5 RECENT DEVELOPMENTS 244
15.4 SCHRDINGER, INC. 245
15.4.1 COMPANY SNAPSHOT 245
15.4.2 REVENUE ANALYSIS 245
15.4.3 COMPANY SHARE ANALYSIS 246
15.4.4 PRODUCT PORTFOLIO 246
15.4.5 RECENT DEVELOPMENT 246
15.5 CRESSET. 247
15.5.1 COMPANY SNAPSHOT 247
15.5.2 COMPANY SHARE ANALYSIS 247
15.5.3 PRODUCT PORTFOLIO 248
15.5.4 RECENT DEVELOPMENTS 248
15.6 ACELLERA LTD 249
15.6.1 COMPANY SNAPSHOT 249
15.6.2 PRODUCT PORTFOLIO 249
15.6.3 RECENT DEVELOPMENTS 249
15.7 ARGUSLAB 250
15.7.1 COMPANY SNAPSHOT 250
15.7.2 PRODUCT PORTFOLIO 250
15.7.3 RECENT DEVELOPMENT 250
15.8 ATOMWISE INC. 251
15.8.1 COMPANY SNAPSHOT 251
15.8.2 PRODUCT PORTFOLIO 251
15.8.3 RECENT DEVELOPMENT 251
15.9 BC PLATFORMS 252
15.9.1 COMPANY SNAPSHOT 252
15.9.2 PRODUCT PORTFOLIO 252
15.9.3 RECENT DEVELOPMENTS 253
15.10 BIOSOLVEIT GMBH 254
15.10.1 COMPANY SNAPSHOT 254
15.10.2 PRODUCT PORTFOLIO 254
15.10.3 RECENT DEVELOPMENT 254
15.11 DOTMATICS 255
15.11.1 COMPANY SNAPSHOT 255
15.11.2 PRODUCT PORTFOLIO 255
15.11.3 RECENT DEVELOPMENTS 256
15.12 GENECODE 257
15.12.1 COMPANY SNAPSHOT 257
15.12.2 PRODUCT PORTFOLIO 257
15.12.3 RECENT DEVELOPMENT 257
15.13 INSILICOTRIALS TECHNOLOGIES. 258
15.13.1 COMPANY SNAPSHOT 258
15.13.2 PRODUCT PORTFOLIO 258
15.13.3 RECENT DEVELOPMENTS 259
15.14 NANOME INC. 260
15.14.1 COMPANY SNAPSHOT 260
15.14.2 PRODUCT PORTFOLIO 260
15.14.3 RECENT DEVELOPMENT 260
15.15 OPTIBRIUM, LTD. 261
15.15.1 COMPANY SNAPSHOT 261
15.15.2 PRODUCT PORTFOLIO 261
15.15.3 RECENT DEVELOPMENT 261
15.16 PHARMACELERA 262
15.16.1 COMPANY SNAPSHOT 262
15.16.2 PRODUCT PORTFOLIO 262
15.16.3 RECENT DEVELOPMENT 262
15.17 SIMULATIONS PLUS. 263
15.17.1 COMPANY SNAPSHOT 263
15.17.2 REVENUE ANALYSIS 264
15.17.3 COMPANY SHARE ANALYSIS 265
15.17.4 PRODUCT PORTFOLIO 265
15.17.5 RECENT DEVELOPMENT 266
15.18 THE SCRIPPS RESEARCH INSTITUTE 267
15.18.1 COMPANY SNAPSHOT 267
15.18.2 PRODUCT PORTFOLIO 267
15.18.3 RECENT DEVELOPMENT 267
15.19 VERISIM LIFE. 268
15.19.1 COMPANY SNAPSHOT 268
15.19.2 PRODUCT PORTFOLIO 268
15.19.3 RECENT DEVELOPMENTS 268
15.20 XTALPI INC. 269
15.20.1 COMPANY SNAPSHOT 269
15.20.2 PRODUCT PORTFOLIO 269
15.20.3 RECENT DEVELOPMENT 269
15.21 XYBION DIGITAL INC. 270
15.21.1 COMPANY SNAPSHOT 270
15.21.2 REVENUE ANALYSIS 270
15.21.3 PRODUCT PORTFOLIO 271
15.21.4 RECENT DEVELOPMENT 271
16 QUESTIONNAIRE 272
17 RELATED REPORTS 276

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.